See pubmed.org faustman. DL
Bcg will do more to prevent autoimmune diseases than oral vaccination with insulin
Desmond Schwartz and Louis Phillips need to read more and debate and discuss
Hayden Murphy andweston deserve an educated choice
Dr. Denise Faustman
Get updates on our research
Keep in touch with the Faustman Lab. Sign up for e-mail updates on the clinical trials and more.
>Sign up
Keep in touch with the Faustman Lab. Sign up for e-mail updates on the clinical trials and more.
>Sign up
>Get information on our clinical trials
For questions about the clinical trial, please e-mail us directly.
>E-mail us
For questions about the clinical trial, please e-mail us directly.
>E-mail us
Follow us
Watch Dr. Faustman's interview about the Phase I trial
Our Phase II Trial Has Launched Read the press release
Interested in the Phase II Trial?
Please email us directly.
------------
Your donation will directly support our Phase II research.
Raised to date: $19 million
Our total need: $25.2 million.
Raised to date: $19 million
Our total need: $25.2 million.
The Faustman Lab at Massachusetts General Hospital
Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. Her current research focuses on discovering and developing new treatments for type 1 diabetes and other autoimmune diseases, including Crohn's disease, lupus, scleroderma, rheumatoid arthritis, Sjögren's syndrome, and multiple sclerosis. She is currently leading a human clinical trial program testing the efficacy of the BCG vaccine for reversal of long-term type 1 diabetes. Positive results from the Phase I study were reported in 2012.Dr. Faustman's type 1 diabetes research has earned her notable awards such as the Oprah Achievement Award for “Top Health Breakthrough by a Female Scientist” (2005), the "Women in Science Award" from the American Medical Women’s Association and Wyeth Pharmaceutical Company for her contributions to autoimmune disease research (2006), and the Goldman Philanthropic Partnerships/Partnership for Cures “George and Judith Goldman Angel Award” for research to find an effective treatment for type 1 diabetes (2011). Her previous research accomplishments include the first scientific description of modifying donor tissue antigens to change their foreignness. This achievement earned her the prestigious National Institutes of Health and National Library of Medicine “Changing the Face of Medicine” Award (2003) as one of 300 American physicians (one of 35 in research) honored for seminal scientific achievements in the United States.
Dr. Faustman earned her MD and PhD from Washington University School of Medicine in St. Louis, Missouri, and completed her internship, residency, and fellowships in Internal Medicine and Endocrinology at the Massachusetts General Hospital in Boston, Massachusetts.
Louis Philipson, MD, PhDProfessor of MedicineDirector, Kovler Diabetes Center
Louis Philipson, MD, PhD, is an endocrinologist and a leading world authority on diabetes mellitus. His clinical interests include type 1 diabetes, complicated type 2 diabetes, monogenic diabetes and hypoglycemia.
Recognized for unmatched expertise in the treatment of diabetes that is difficult to manage, Dr. Philipson's multisciplinary team frequently accepts referrals and provides consultations. Under his leadership, Kovler Diabetes Center has been recognized as a one of only seven National Institutes of Health (NIH) Diabetes Research and Training Centers in the U.S.
For more than 25 years, Dr. Philipson has tirelessly explored the biophysical, molecular and genetic aspects of insulin secretion, and the genetics of diabetes. He and his colleagues discovered rare insulin gene mutations that produce beta cell ER stress and, in turn, cause neonatal diabetes.
In addition, Dr. Philipson and his colleagues are among the nation's leading experts on monogenic diabetes, following more than 100 patients diagnosed with neonatal diabetes and many others with maturity onset diabetes of the young (MODY) type diabetes. He also serves as co-director of the Human Islet Transplantation project at the University of Chicago.
Dr. Philipson has served as principal investigator on numerous research projects. His work is widely published in biomedical journals, including the Proceedings of the National Academy of Sciences, Science, Nature, Diabetes, American Journal of Physiology and the Journal of Biological Chemistry.
As president of the Chicago/Northern Illinois board of the American Diabetes Association and a member of its National Board, he has been invited to speak and present at scientific research conferences and symposia worldwide. In addition, Dr. Philipson is the recipient of numerous awards including ADA Research Awards and the National Disease Research Interchange (NDRI) Outstanding Scientist Award. He was also named the 2011 recipient of the Samuel Eichold II Memorial Award for Contributions in Diabetes by the American College of Physicians.
Practice Locations
The University of Chicago Medicine
5841 S. Maryland Avenue Chicago, IL 60637
Duchossois Center for Advanced Medicine
5758 S. Maryland Avenue Chicago, IL 60637 Year Started Practice
1986
Board Certifications
Endocrine, Diabetes & Metabolism
Internal Medicine Medical School
The University of Chicago Pritzker School of Medicine
Internship, Residency and Fellowship
The University of Chicago Medicine
Additional Graduate Degree
PhD, University of Chicago (Biochemistry)
Memberships
American College of Physicians
American Diabetes Association Juvenile Diabetes Foundation International European Society for Study of Diabetes Language Spoken
English
Office PhoneOffice FaxOffice Postal Address
Louis Philipson, MD, PhD
The University of Chicago Medicine 5841 S. Maryland Avenue, MC 1027 Chicago, IL 60637 |  Clinical Interests
Learn More About Dr. Philipson
Learn more about Dr. Philipson and his colleagues in the University of Chicago Kovler Diabetes Center.
Dr. Philipson is featured in"Journey to a Miracle: Freedom from Insulin," an independent documentary that focuses on the discovery of a groundbreaking discovery for monogenic diabetes.
Through his innovative research, Dr. Philipson uncovered a rare form of diabetes caused by a genetic mutation and developed a successful treatment.
Lilly Jaffe was diagnosed with a rare type of diabetes when she was just one month old. Dr. Philipson helped her to produce insulin, making Lilly the fourth such case to be treated in the United States.Read her story.
What Joey Knoop thought was just a cold turned out to be type 1 diabetes. After struggling with her blood sugar levels for year, Knoop was referred to Dr. Philipson and underwent an islet cell transplant to produce her own insulin. Read Joey’s story.
The University of Chicago Medicine's Science Life blog features Dr. Philipson in a video about the real human effects of a scientific breakthrough in diabetes care.
Dr. Philipson was featured in a video about diabetes research and patient care, which aired on Comcast's "Policy Makers."
Dr. Philipson, along with members of congress, was part of the team that declared an inaugural Diabetes Awareness Day in Illinois. Read the story.
Selected Publications
View a partial list of Dr. Philipson's publications through the National Library of Medicine's PubMed online database.
|
In this photo taken Wednesday, May 13, 2015, Hayden Murphy, 13, sits for a photo with his medicine at his home in Plainfield, Ill. Hayden is among more than 400 children and adults participating in U.S. government-funded international research investigating whether experimental insulin capsules can prevent or at least delay Type 1 diabetes. To enroll, participants must first get bad news: results of a blood test showing their chances for developing the disease are high. (AP Photo/Nam Y. Huh) Photo Credit: AP
CHICAGO - (AP) -- For nearly a century, insulin has been a life-saving diabetes treatment. Now scientists are testing a tantalizing question: What if pills containing the same medicine patients inject every day could also prevent the disease?
Thirteen-year-old Hayden Murphy of Plainfield, Illinois, is helping researchers determine if the strategy works for Type 1 diabetes, the kind that is usually diagnosed in childhood. If it does, he might be able to avoid the lifetime burdens facing his 5-year-old brother, Weston. They includes countless finger pricks and blood sugar checks, and avoiding playing too hard or eating too little, which both can cause dangerous blood sugar fluctuations.
Hayden Murphy is among more than 400 children and adults participating in U.S. government-funded international research investigating whether experimental insulin capsules can prevent or at least delay Type 1 diabetes. Hospitals in the United States and eight other countries are involved and recruitment is ongoing. To enroll, participants must first get bad news: results of a blood test showing their chances for developing the disease are high.
"When I got the news, I was devastated," Hayden said. He knows it means his life could change in an instant.
No comments:
Post a Comment